Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

Next Previous
Trial Profile

A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu AG13909 (Primary) ; Lu AG13909 (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Lundbeck A/S

Most Recent Events

  • 11 May 2025 Planned End Date changed from 15 Dec 2027 to 15 Mar 2028.
  • 02 Dec 2024 Planned End Date changed from 15 May 2026 to 15 Dec 2027.
  • 02 Dec 2024 Planned primary completion date changed from 7 Feb 2026 to 15 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top